

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

Head Office Address: 88 Truong Chinh, Dong Da, Hanoi
Phone Number : 0243.8691262 | Fax: 0243.8691263
Email: info@vinavetco.com | Website: <http://www.vinavetco.com>
Business code : 0100102326

REGULATIONS ON THE ORGANIZATION OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS IN 2025

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

- Based on the Enterprise Law No. 59/2020/QH14 dated June 17, 2020;
- Based on the Securities Law No. 54/2019/QH14 dated November 26, 2019;
- Based on Decree 155/2020/ND-CP dated December 31, 2020 and guiding documents;
- Based on the Charter of Organization and Operation of Central Veterinary products Joint Stock Company I.

I. GENERAL PROVISIONS

1. scope of application

- This regulation applies to the organization of the Annual General Meeting of Shareholders in 2025 (hereinafter referred to as the "Meeting") of Central Veterinary products Joint Stock Company I.
- This regulation specifically stipulates the rights and obligations of Shareholders and participants in the Meeting, conditions, and procedures for conducting the Meeting.

2. Conditions for attending the Congress:

the Meeting Shareholders whose names are on the list of Shareholders on the record date for attending the Meeting or authorized representatives of Shareholders.

3. Conditions for conducting the Meeting

The Meeting is conducted when the number of shareholders/authorized representatives of shareholders attending the meeting represents over 50% of the total voting shares according to the list of shareholders of the Company established on the record date for the list of shareholders attending the Meeting (April 23, 2025).

II. EXECUTIVE BODY AND ASSISTANCE FOR THE MEETING

The Meeting decides on the number and specific list of the Presidium, Secretariat, Shareholder Qualification Inspection Committee, and Inspection Committee.

1. Presidium

The work of the Meeting is managed by the Presidium elected by the Meeting.

The tasks of the Presidium: Conduct the activities of the Meeting according to the program and regulations approved by the Meeting.

Maintaining the Discussion of Shareholders

Maintain the discussion part of the shareholders. Respond to the issues requested by the Congress. Conclude the issues discussed at the Congress, manage the minutes and resolutions of the Congress.

2. Secretariat

-The Secretariat is the department assisting the Chairman's Delegation, working under the direction of the Chairman's Delegation.

-The tasks of the Secretariat:

Record the minutes of the Congress reflecting the contents and issues mentioned by the Congress. Summarize the discussion opinions at the Congress. Draft the minutes and resolutions of the Congress. Receive and transfer to the Chairman's Delegation the questionnaires/comments from shareholders, documents related to the Congress. Collect, preserve, and send to the Company's Board of Directors the feedback forms from shareholders at the Congress. Other tasks as assigned by the Chairman's Delegation.

3. Ballot Counting Committee

The Ballot Counting Committee is the assisting department of the organizing committee and the Chairman's Delegation, working under the direction of the Chairman's Delegation.

The tasks of the Ballot Counting Committee:

Guide and supervise the voting of shareholders at the Congress. Summarize the number of shares voted on each voting content and announce the voting results before the Congress. Other tasks as assigned by the Chairman's Delegation.

III. RIGHTS AND OBLIGATIONS OF SHAREHOLDERS, AUTHORIZED REPRESENTATIVES OF SHAREHOLDERS

Shareholders and authorized representatives of shareholders have the right to attend, discuss, and vote on all issues within the authority and according to the Program of the Congress.

The Chairman's Delegation will publicly announce the Program of the Congress; the opinions of shareholders and authorized representatives of shareholders at the Congress will be discussed publicly.

At the Congress meeting, shareholders and authorized representatives of shareholders will hear the report contents and the contents presented by the Board of Directors mentioned in

the Program. conference, discussion and approval of each content in the form of voting cards or ballot papers.

Seriously comply with the working regulations of the conference, respect the results of the conference and the management of the Presidium.

IV. INFORMATION AND SPEECH REGIME IN THE CONFERENCE

The Presidium decides on information about the conference, based on compliance with the law and the interests of the Company.

All shareholders have the right to discuss issues related to the agenda of the conference.

Shareholders who wish to discuss at the conference should register their speech content using the shareholder question/comment form provided by the organizing committee and clearly state the discussion issue, sending it to the secretariat for compilation, reporting to the Presidium to organize the discussion of each issue.

Method of speaking: When expressing opinions, shareholders are invited to the podium at the speaking position designated by the Presidium. Shareholders should speak briefly and focus on the key contents that need to be exchanged, in accordance with the registered speech content and the approved conference agenda. The Presidium will arrange for shareholders to speak in the order of registration, while also addressing shareholders' questions. Issues that have been voted on by the conference will not be discussed again. Issues that shareholders registered to discuss but were not addressed within the discussion time according to the approved conference agenda will be considered by the Board of Directors and answered to shareholders in an appropriate manner after the conference.

The Presidium of the conference has the right to remind or request shareholders to focus on the key content that needs to be expressed to save time and ensure the quality of the discussion.

V. PRINCIPLES OF VOTING ON ISSUES AT THE CONFERENCE

Shareholders will vote on issues at the conference using voting cards and ballot papers.

1. Voting Cards; Ballot Papers

Each shareholder is issued a voting card and a ballot paper printed and stamped by the Company.

+ The voting card will be used to collect votes on the following issues:

- Approving the personnel of the Presidium, the Secretariat, the ballot counting - committee;
- Approving the conference agenda, the organization regulations of the conference, the minutes, the resolutions of the conference;

- Other issues within the authority of the general shareholders' meeting (if any).

For the above issues, shareholders are requested to raise their voting cards, with the front of the voting card showing the number of shares owned or represented facing the Presidium.

2. Voting Procedures

The voting contents recorded on the Voting Card will be voted on by shareholders/authorized representatives of shareholders by choosing the voting opinion "Agree," "Disagree," or "Have no opinion" for each voting content (marking the corresponding voting opinion for each voting content).

Shareholders vote according to the following principles: Voting begins when signaled by the Chairman of the meeting or the Head of the Vote Counting Committee and ends when the last shareholder votes into the ballot box or after 20 minutes from the start of voting, depending on which comes first. The vote counting will be conducted immediately after the voting ends.

Invalid voting cards: Cards not following the prescribed template, not issued by the Company, lacking the Company's seal; Cards that are crossed out, corrected, added to, or incorrectly named; Cards that are torn, not intact; Cards that contain additional information, added symbols; Cards that are not marked in any voting opinion box and/or are marked in two or more boxes for each voting content; Cards lacking the signature of the shareholder or the authorized representative of the shareholder.

Voting on each voting content in the Voting Card is independent of each other; the validity of the vote on this content does not affect the validity of other voting contents.

In the event that a shareholder, during the voting process, mistakenly fills out the Voting Card, if it has not been placed in the ballot box and the voting time has not expired, they have the right to directly meet the Head of the Vote Counting Committee to request a replacement Voting Card to ensure the rights of the shareholder.

3. The voting results

The voting results will be announced by the Vote Counting Committee after compiling the voting results for all issues in the agenda.

VI. CONDITIONS FOR PASSING THE DECISION OF THE GENERAL MEETING¹

1. One (01) common share is equivalent to one (01) voting right.
2. The following issues are approved when the number of shareholders representing at least 65% of the total voting shares of all attending shareholders agrees: Proposal to amend the charter Amendments and supplements to the contents of the Company Charter; and some issues recorded in Article 21 of the Company Charter.
3. Other resolutions are approved when the number of shareholders owning over 50% (fifty percent) of the total voting shares of all attending shareholders agrees (in the case of holding a direct meeting) or over 50% of the total votes of shareholders with voting rights agree (in the

case of collecting opinions from shareholders in writing), except for the cases specified in clauses 3, 4, and 6 of Article 148 of the Enterprise Law.

4. The voting for members of the Board of Directors and the Supervisory Board is conducted by cumulative voting, whereby each shareholder has a total number of voting shares corresponding to the total number of shares owned multiplied by the number of members to be elected of the Board of Directors or the Supervisory Board, and shareholders have the right to allocate all or part of their total votes to one or several candidates. The elected members of the Board of Directors or the Supervisory Board are determined by the number of votes counted from highest to lowest, starting from the candidate with the highest number of votes until the required number of members as stipulated in the Company Charter is reached. In the case of two or more candidates receiving the same number of votes for the last member of the Board of Directors or the Supervisory Board, a re-vote will be conducted among the candidates with the same number of votes or selected according to the election regulations.

5. Other issues under the authority of the General Meeting of Shareholders (if any) in accordance with the provisions of the Enterprise Law and the Charter of organization and operation of the Company.

VII. SOME ISSUES AT THE MEETING

1. Use of mobile phones:

To ensure the meeting is conducted seriously, with quality, and achieves good results, the organizing committee requests that distinguished representatives and shareholders turn off their mobile phones or set them to silent mode. If it is necessary to use the phone, please step outside to talk so as not to affect the meeting.

2. Smoking in the hall:

During the meeting, it is requested that attendees do not smoke in the hall to ensure fire safety and a shared living environment. If any attendees wish to smoke, please do so in designated areas suitable for the benefit of the community.

3. Press and media:

No filming, photography, or recording is allowed without the consent of the Presidium during the meeting.

No information may be transmitted outside in any form until the conclusion of the meeting.

VIII. RESPONSIBILITY FOR IMPLEMENTATION

+ The Presidium, the Secretariat, the Shareholder Eligibility Verification Committee, the Ballot Counting Committee, the delegates, and the shareholders/shareholder representatives must comply with the working regulations of the General Meeting.

+ **Sanctions applied:** In the event that any individual violates these Regulations, they will be expelled from the General Meeting by the Presidium.

IX. MINUTES AND RESOLUTIONS OF THE GENERAL MEETING OF SHAREHOLDERS

All main contents of the General Meeting of Shareholders must be recorded by the Secretary of the Meeting in the minutes of the Meeting. The minutes and resolutions of the General Meeting of Shareholders are to be read and approved before the Meeting is adjourned.

Above is the entire Regulation for organizing the annual General Meeting of Shareholders in 2025 of Central Veterinary products Joint Stock Company I.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

**ON BEHALF OF THE BOARD OF
DIRECTORS**

chairman of the board of directors



NGUYỄN ANH TUẤN



Hanoi, April 1, 2025

REPORT

ON THE ACTIVITIES OF THE BOARD OF DIRECTORS *VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I*

Dear General Meeting: First of all, as Chairman of the Board of Directors for the 7th term, I sincerely thank the Shareholders for always supporting and creating all conditions for the Board of Directors and the Executive Board to successfully complete the targets assigned by the General Meeting of Shareholders.

Dear General Meeting: Implementing the Charter on the organization and operation of Central Veterinary products Joint Stock Company I approved by the General Meeting of Shareholders on May 6, 2023; Resolution of the Annual General Meeting of Shareholders in 2024.

On behalf of the Board of Directors, I would like to report to the General Meeting of Shareholders on the activities of the Board of Directors in 2024 and the plan for 2025 as follows:

PART I: ASSESSMENT OF THE COMPANY'S SITUATION IN 2024

1. ABOUT PERSONNEL

In 2024, the personnel situation of the entire Company remains stable, including:

The Board of Directors of Central Veterinary products Joint Stock Company I in 2024 has 3 members including: 01 Chairman of the Board of Directors and 02 members.

The Executive Board includes: The Chairman of the Board of Directors directly manages the departments including: Director, Chief Accountant, Head of Internal Affairs Department and Director of Central Veterinary Company Limited 1



2. ON THE COMPANY'S PRODUCTION AND BUSINESS RESULTS IN 2024

2024 is a difficult year for the world economy in general, with a decline in global GDP growth, trade and investment; while inflation remains high, associated with tense developments in geopolitical conflicts and technological fragmentation, extreme weather and widespread epidemics, the world economic context has many rapid, unpredictable fluctuations and high instability; natural disasters, epidemics, climate change, storms, droughts... have increased risks to financial markets, currencies, energy security, and global food security. Global potential growth is expected to fall to its lowest level in the past three decades.

Although in 2024 the Company had financial solutions, gradually implementing business activities to stabilize. Besides, in 2024, fluctuations in the financial situation of society, specifically fluctuations in foreign exchange rates in the market, were more stable,

Raw materials and livestock supplies have a decreasing trend, but the prices of raw materials for veterinary medicine production are still rising, leading to a significant impact on the profits achieved during the year.

The Board of Directors has actively sought solutions and investors to enhance capital sources. The Board of Directors presented to the General Meeting of Shareholders and was entrusted by the extraordinary General Meeting of Shareholders to implement.

From the above advantages and difficulties, the production and business activities of Central Veterinary Medicine Joint Stock Company I in 2024 are as follows:

CONSOLIDATED INCOME STATEMENT 2024

Unit: Thousand Dong

ITEMS	2023	2024	% increase or decrease
Revenue from sales of goods and rendering of services	97.602.141.142	112.835.573.099	15,61
Operating profit	2.588.981.277	4.274.591.547	65,11
Other expenses	1.679.796.176	819.054.964	-51,24
Net profit before tax	4.268.778.453	5.093.646.511	19,32
Net profit after tax	3.381.284.688	3.777.670.212	11,72

(Data from the 2024 financial statements will be presented by the Board of Directors in the financial report).

Looking at the table of business production results, we see that in 2024, the company has utilized the newly invested workshop, so the business results increased compared to

2023. Specifically, sales increased by 15.51%, and profit after tax increased by 11.72%. Although the extraordinary income in 2024 decreased compared to 2023 by 51.24%.

In recent years, the Board of Directors of the company has implemented many solutions to overcome existing issues and gradually stabilize and develop the company. Alongside significant successes, the company still faces some unresolved financial difficulties, which are debts to suppliers. Although the Board of Directors and the Executive Board have made efforts to implement business plans, consolidate and maintain the old market while expanding the market, enhancing technical work to improve product quality, and developing additional new products and product lines that meet market preferences

In 2024, the production sales increased compared to 2023 by 14,203,166,482 VND, equivalent to 34.13%, due to the efforts of employees who have worked hard to develop the market, along with additional products produced from the betalactam workshop, which is also a factor for increased sales revenue.

For the vaccine products, which are the products the company trades, in 2024, there was an increase of 2,692,550,818 VND, equivalent to 5.27% compared to 2023. This shows that in 2024, the overall business results of the company increased, primarily due to the following reasons:

2.1. Business Situation of Veterinary Medicine of the Company in 2024:

Comparing the business results of veterinary medicine in 2024 with 2023, there was an increase of 34.13% due to several reasons: In 2024, the company has strengthened product quality improvements and completed new product lines, leading to a significant increase in Central Veterinary products Joint Stock Company I sales.

In addition, the company has changes in management personnel as well as restructuring the entire sales department personnel, therefore, although the company has improvements in technology as well as in product quality, the level of promotion is still not high. This is also a reason that directly affects the production and business results of the Central Veterinary products Joint Stock Company I in 2024.

2.2. Business situation of vaccines: In 2024, vaccine sales increased by 5.27% compared to 2023. However, the biggest influencing factor is that our vaccines are imported goods. Currently, there are many competing products in the domestic market in terms of market and price, so in 2024, the Company still maintains vaccine sales to keep the market stable. In addition, potential customers are opened, but sales growth is still not high.

2.3. Business situation of services: In 2024, due to difficulties in commercial business, the partner renting the property at 88 Truong Chinh has returned the premises, leading to a decrease in revenue for the parent company, and profits in 2024 decreased.

3. Capital and shares situation in 2024:

- Charter capital in 2024: : 162.499.690.000 VND
- Total number of shares : 16.249.969 shares..

Among them

- Number of shares in circulation : 16.249.956 common shares.
- Treasury shares of the Company : 13 shares.

Total number of shareholders as of March 26, 2025 : 292 Shareholders

4. Regarding relations with shareholders:

The Company has complied with information disclosure according to the law and applicable legal documents for large-scale public companies and listed organizations. In addition, the relationship with shareholders is maintained regularly and actively through the website and the information disclosure person of the Company.

PART II: ASSESSMENT OF THE OPERATION SITUATION OF THE BOARD OF DIRECTORS

1. Situation of implementing the resolutions of the Board of Directors in 2024.

In the face of fierce competition in the market for businesses in the same industry today, in addition to overcoming the difficulties left over from previous years, the Board of Directors still focuses all resources to maintain and develop the production and business activities of Veterinary Medicine of the Company, seeking every way to connect sustainably with customers who are long-term partners of the Company. Therefore, in 2024, the sales of veterinary medicine have increased significantly by 34.13%.

For vaccine products: The Company continues to maintain a large customer system. In addition, some farms have been brought in. Sales in 2024 also increased by 5.27% compared to 2023 but still decreased significantly compared to 2022.

The Board of Directors has implemented the resolution of the 2024 shareholders' meeting through several specific main objectives as follows:

General objective: In 2024, the Company always promotes and maintains the strong reputation of the VINAVETCO brand in the field of investment and business in veterinary medicine, aquatic drugs, and various types of vaccines. The Company has been and is gradually stabilizing, developing sustainably while gradually expanding its operational market to provinces and cities across the country. Focus on improving and diversifying products to suit the general situation, continuously enhancing product quality at reasonable prices suitable for consumers.

Business Production Goals:

Strengthening the business of products that are already on the market, while also researching and developing additional new products that are diverse and rich in types for animals, pets, livestock, and poultry, from medicines for disease prevention and treatment, deworming medicines, health supplements, growth stimulants to reproductive regulation medicines, parasitocidal medicines, and antifungal medicines.

To ensure the development of business activities, the Board of Directors along with the Executive Board has devised a plan to review the entire customer system nationwide to regain market share, restore customer trust with appropriate policies to develop and support agents in the short term to maintain sales and gradually increase sales.

Financial Goals: On 10-02-2023, the Board of Directors completed the plan and increased the charter capital of the Company to 162,499,690,000 VND. The completion of the Betalactam workshop in 2023 will allow Betalactam products to start entering the market again in 2024.

Human Resource Goals: The company continuously organizes and trains to improve the quality of the workforce in terms of quantity and quality, while regularly recruiting experienced staff to supplement the sales team.

Structure of the Board of Directors:

The Board of Directors of the company from 01/01/2024 to 04/05/2024 consists of 03 members, including:

No.	Name	Title	Position
1	Nguyen Anh Tuan	Chairman of the Board of Directors	Chairman of the BoD – Executive Member
2	Bui Huong Lien	Commissioner	Non-executive Member of the BoD
3	Nguyen Viet Hoang	Commissioner	Independent Member of the BoD

The Board of Directors of the company from 06/05/2023 to 31/12/2023 consists of 03 members:

No.	Name	Title	Position
1	Nguyen Anh Tuan	Chairman of the Board of Directors	Chairman of the BoD – Executive Member
2	Phan Quoc Duy	Commissioner	Non-executive Member of the BoD
3	Nguyen Viet Hoang	Commissioner	Independent Member of the BoD

2. About the organization of the Board of Directors meetings.

To implement work in a regular, frequent, and timely manner, in the year 2024, the Board of Directors of the Company has organized direct meetings. The meetings have been conducted in accordance with the procedures and regulations specified in the Charter of the Central Veterinary Pharmaceutical Joint Stock Company and the Enterprise Law. The minutes of the Board of Directors meetings have been fully signed by the participating Board members, ensuring compliance with the legal requirements; documents and materials have been fully sent to the attending members for reference and study in accordance with the provisions of the Charter.

The resolutions of the Board of Directors issued in the year include:

No.	Date	Resolution number	Content
1	06/03/2024	02-2024/NQ-HĐQT	Resolution of the Board of Directors meeting to finalize the date of the 2024 shareholders' meeting
2	06/03/2024	03-2024/QĐ-CTHĐQT	Decision to establish the organizing committee of the General Meeting of Shareholders
3	06/03/2024	04-2024/QĐ-CTHĐQT	Decision of the Chairman of the Board of Directors on fund allocation
4	15/03/2024	06-2024/NQ-HĐQT	Resolution of the Board of Directors meeting to postpone the 2024 annual shareholders' meeting
5	02/04/2024	08-2024/NQ-HĐQT	Resolution of the Board of Directors meeting to approve the Report to be submitted to the General Meeting of Shareholders
6	04/05/2024	Số 19-2023/NQ-ĐHĐCĐ	Resolution of the 2024 Annual General Meeting of Shareholders
7	04/05/2024	21-2024/NQ-HĐQT	Resolution of the Board of Directors meeting to approve the election of the member of the Inspection Committee
8	25/07/2024	22-2024/QĐ-CTHĐQT	Decision of the Company's Board of Directors on transferring the LLC's profits for the first 6 months of 2024 to the company
9	30/08/2024	24-2024/NQ-HĐQT	Resolution of the Board of Directors meeting on mortgaging assets to the company's bank for the LLC
10	28/10/2024	26-2024/NQ-HĐQT	Resolution of the Board of Directors meeting on the appointment of the person in charge of corporate governance
11	28/10/2024	27-2024/ QĐ-CTHĐQT	Decision to appoint person in charge of corporate governance

PART III: FINANCIAL REPORT FOR THE YEAR 2024

CONSOLIDATED BALANCE SHEET

As at 31 December 2024

ASSETS	Code	Note	31/12/2024 VND	01/01/2024 VND
CURRENT ASSETS	100		59,693,573,390	50,438,415,582
Cash and cash equivalents	110	4	28,209,029,640	24,171,520,460
Cash	111		6,887,029,640	10,734,520,460
Cash equivalents	112		21,322,000,000	13,437,000,000
Current accounts receivables	130		10,252,671,297	6,690,200,055
Short-term trade receivables	131	7	11,501,916,707	8,865,061,546
Short-term advances to suppliers	132	8	1,564,831,000	828,294,792
Other short-term receivables	136	10	4,454,169,129	4,265,089,256
Allowance for doubtful short-term	137	11	(7,268,245,539)	(7,268,245,539)
Inventories	140	9	19,444,138,888	17,446,220,537
Inventories	141		21,334,861,658	19,289,321,310
Provision for decline in inventories	149		(1,890,722,770)	(1,843,100,773)
Other current assets	150		1,787,733,565	2,130,474,530
Short-term prepaid expenses	151	5	277,093,435	415,245,948
Deductible value added tax	152		1,320,066,631	1,715,228,582
Taxes and other receivables from the State	153	15	190,573,499	-
NON-CURRENT ASSETS	200		96,082,908,132	100,746,612,968
Non-current accounts receivables	210		19,965,000	19,965,000
Other long-term receivables	216	10	19,965,000	19,965,000
Fixed assets	220		94,731,229,420	99,590,696,538
Tangible fixed assets	221	12	93,532,686,424	98,272,299,234
- Cost	222		165,217,987,866	164,145,087,866
- Accumulated depreciation	223		(71,685,301,442)	(65,872,788,632)
Intangible fixed assets	227	13	1,198,542,996	1,318,397,304
- Cost	228		2,416,877,460	2,416,877,460
- Accumulated amortization	229		(1,218,334,464)	(1,098,480,156)
Long-term financial investments	250	6	-	-
Investments in other entities	253		866,640,000	866,640,000
Provision for long-term financial	254		(866,640,000)	(866,640,000)
Other long-term assets	260		1,331,713,712	1,135,951,430
Long-term prepaid expenses	261	5	1,331,713,712	1,135,951,430
TOTAL ASSETS	270		155,776,481,522	151,185,028,550

CONSOLIDATED BALANCE SHEET (CONT'D)

As at 31 December 2024

RESOURCES	Code	Note	31/12/2024 VND	01/01/2024 VND
LIABILITIES	300		54,381,724,462	53,367,941,702
Current liabilities	310		42,042,724,462	41,548,941,702
Short-term trade payables	311	14	23,935,611,810	25,587,473,439
Short-term advances from customers	312		311,292,114	46,720,730
Taxes and other payables to the State	313	15	1,560,370,236	975,361,316
Payables to employees	314		6,393,780,663	5,266,455,107
Short-term accrued expenses	315	17	4,399,433,352	4,154,432,573
Short-term unearned revenue	318		15,000,000	-
Other short-term payables	319	18	4,738,179,361	4,784,641,611
Bonus and welfare fund	322		689,056,926	733,856,926
Non-current liabilities	330		12,339,000,000	11,819,000,000
Other long-term payables	337	18	539,000,000	19,000,000
Long-term loan and finance lease	338	16	11,800,000,000	11,800,000,000
OWNERS' EQUITY	400		101,394,757,060	97,817,086,848
Capital	410	19	101,394,757,060	97,817,086,848
Share capital	411		162,499,690,000	162,499,690,000
- Ordinary shares with voting rights	411a		162,499,690,000	162,499,690,000
Other capital of owners	414		278,962,752	278,962,752
Treasury shares	415		(130,000)	(130,000)
Development investment funds	418		3,559,312,727	3,559,312,727
Retained earnings	421		(64,943,078,419)	(68,520,748,631)
- Accumulated retained earnings brought forward	421a		(68,520,748,631)	(71,652,033,319)
- Retained earnings for the current year	421b		3,577,670,212	3,131,284,688
TOTAL RESOURCES	440		155,776,481,522	151,185,028,550

Hanoi, 28 March 2025

Preparer




Nguyen Thi Phuong

Chief Accountant



Nguyen Thi Thu Ha

Chairman



Nguyen Anh Tuan

CONSOLIDATED INCOME STATEMENT
For the financial year ended 31 December 2024

Items	Code	Note	Year 2024 VND	Year 2023 VND
Revenue from sales of goods and rendering of services	01	20	112,835,573,099	97,602,141,142
Revenue deductions	02	21	3,721,888,494	3,262,656,485
Net revenue from sales of goods and rendering of services	10		109,113,684,605	94,339,484,657
Cost of goods sold	11	22	81,890,664,520	70,890,591,630
Gross profit from sales of goods and rendering of services	20		27,223,020,085	23,448,893,027
Financial income	21	23	588,623,333	546,117,635
Financial expenses	22	24	851,079,637	666,642,094
<i>In which: Interest expenses</i>	23		-	-
Selling expenses	25	25	12,814,330,333	11,767,874,117
General and administrative expenses	26	25	9,871,641,901	8,971,513,174
Operating profit	30		4,274,591,547	2,588,981,277
Other income	31	26	1,002,070,898	1,803,081,956
Other expenses	32	27	183,015,934	123,284,780
Other profit	40		819,054,964	1,679,797,176
Net profit before tax	50		5,093,646,511	4,268,778,453
Current Corporate income tax expenses	51	29	1,315,976,299	887,493,765
Deferred Corporate income tax expenses	52		-	-
Net profit after tax	60		3,777,670,212	3,381,284,688
Basis Earnings per share	70	30	220	195
Diluted Earnings per share	71	31	220	195

Hanoi, 28 March 2025

Preparer



Nguyen Thi Phuong

Chief Accountant



Nguyen Thi Thu Ha

Chairman



Nguyen Anh Tuan

STATEMENT OF THE BOARD OF DIRECTORS

The Board of Directors of Viet Nam Veterinary Products Joint Stock Company (hereinafter referred to as "the Company") presents this report together with the audited Consolidated Financial Statements for the financial year ended 31 December 2024.

BOARD OF MANAGEMENT AND BOARD OF DIRECTORS

Members of the Board of Management and Board of Directors of Company who held office during the financial year ended 31 December 2024 and up to the date of this report are as follows:

Board of Management

Mr. Nguyen Anh Tuan	Chairman
Mr. Nguyen Viet Hoang	Member
Ms. Bui Huong Lien	Member (Dismissed on 04 May 2024)
Mr. Phan Quoc Duy	Member (Appointed on 04 May 2024)

Audit Committee

Mr. Nguyen Viet Hoang	Chairman of Audit Committee
Ms. Bui Huong Lien	Member (Dismissed on 04 May 2024)
Mr. Phan Quoc Duy	Member (Appointed on 04 May 2024)

Board of Directors and Chief Accountant

Ms. Nguyen Thi Thu Hung	Director
Ms. Nguyen Thi Thu Ha	Chief Accountant

Information disclosed by Ms. Nguyen Thi Phuong - Head of the Internal Affairs Department.

SUBSEQUENT EVENTS AFTER THE END OF THE FINANCIAL YEAR

The Board of Directors confirms that no significant events have occurred after the balance sheet date that would materially effect, require adjustment, or necessitate disclosures in these Consolidated Financial Statements.

THE AUDITOR

The accompanying Consolidated Financial Statements have been audited by UHY Auditing and Consulting Company Limited.

BOARD OF DIRECTORS STATEMENT OF RESPONSIBILITY

The Board of Directors of the Company is responsible for preparing the Consolidated Financial Statements which give a true and fair view of the financial position of the Company for the year ended 31 December 2024 and its results of operations and cash flows for the year then ended. In preparing these Consolidated Financial Statements, the Board of Directors is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting principles have been followed, subject to any material departures disclosed and explained in the Consolidated Financial Statements;
- Prepare the Consolidated Financial Statements on a going concern basis unless it is inappropriate to presume that Company will continue its operations;

STATEMENT OF THE BOARD OF DIRECTORS (CONT'D)

BOARD OF DIRECTORS STATEMENT OF RESPONSIBILITY (CONT'D)

- Design and implement an effective system of internal controls to ensure the fair preparation and presentation of the Consolidated Financial Statements, minimizing risks and preventing fraud.


The Board of Directors confirms that the Company has complied with the above requirements in preparing the Consolidated Financial Statements.

The Board of Directors is responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the consolidated financial position of the Company and ensure that the Consolidated Financial Statements comply with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and related legal regulations on the preparation and presentation of the Consolidated Financial Statements in Vietnam. It is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

OTHER COMMITMENTS

The Board of Directors commits that the Company does not violate its obligation to disclose information as prescribed in Circular No. 96/2020/TT-BTC on 16 November 2020 issued by the Ministry of Finance regarding securities market disclosure, complying with the provisions of Decree No.155/2020/ND-CP on 31 December 2020 issued by the Government, which details the implementation of certain provisions of the securities law, and Circular No. 116/2020/TT-BTC dated 31 December 2020 issued by Ministry of Finance, which provides guidelines on corporate governance applicable to public companies under Decree No. 155/2020/ND-CP.

For and on behalf of the Board of Directors,



Nguyễn Anh Tuan
Chairman

Hanoi, 28 March 2025

No: 392 /2025/UHY-BCKT

INDEPENDENT AUDITORS' REPORT

*On the Consolidated Financial Statements of Viet Nam Veterinary Products Joint Stock Company
For the financial year ended 31 December 2024*

**To: Shareholders
Board of Directors
Viet Nam Veterinary Products Joint Stock Company**

We have audited the accompanying Consolidated Financial Statements of Viet Nam Veterinary Products Joint Stock Company (hereinafter referred to as the "Company") which were prepared on 28 March 2025 as set out on pages 06 to 40, including the Consolidated Balance Sheet as at 31 December 2024, the Consolidated Income Statement and the Consolidated Cash Flow Statement for the financial year then ended and the Notes thereto.

Responsibilities of the Board of Directors

The Board of Directors of the Company is responsible for the preparation and fair presentation of these Consolidated Financial Statements in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System, and related legal regulations on the preparation and presentation of the Consolidated Financial Statements in Vietnam and for such internal control as the Board of General Directors determines is necessary to enable the preparation and presentation of the Consolidated Financial Statements that are free from material misstatements, whether due to fraud or error.

Responsibilities of the Auditors

Our responsibility is to express an opinion on these Consolidated Financial Statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the Consolidated Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Consolidated Financial Statements. The selected procedures depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Consolidated Financial Statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Board of Directors, as well as evaluating the overall presentation of the Consolidated Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

INDEPENDENT AUDITORS' REPORT (CONT'D)

Opinion of the Auditors

In our opinion, the accompanying Consolidated Financial Statements give a true and fair view, in all material respects, of the consolidated financial position of Viet Nam Veterinary Products Joint Stock Company as at 31 December 2024 and the results of its consolidated operations and its cash flows for the financial year then ended, in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and legal regulations related to the preparation and presentation of the Consolidated Financial Statements.



Nguyễn Minh Long
Deputy General Director
Auditor's Practicing Certificate
No. 0666-2023-112-1

For and on behalf of

UHY AUDITING AND CONSULTING COMPANY LIMITED
Hanoi, 28 March 2025

A handwritten signature in black ink, appearing to read 'Thang', written over a horizontal line.

Nguyen Minh Thang
Auditor
Auditor's Practicing Certificate
No. 4421-2023-112-1

PART IV: PROFIT DISTRIBUTION, REMUNERATION FOR THE BOARD OF DIRECTORS, AUDIT COMMITTEE OF THE COMPANY IN 2024

I. Profit distribution plan

Profit distribution plan for 2024The company has made a profit of:3,577,670,212 VNDbut due to the company's financial situation being in a state of accumulated losses,the accumulated loss as of 31/12/2024 is still 64,943,078,419 VNDso in 2024 there will be no dividend payment.

II. Remuneration for the Board of Directors and the Audit

CommitteeAccording to the resolution of the General Meeting of Shareholders in 2024, the remuneration for the Board of Directors and the Audit Committee is specified as follows

Unit: VND			
No.	INTERPRETATION	AMOUNT OF REMUNERATION RECEIVED	AMOUNT OF REMUNERATION RECEIVED
1	Board of Directors	84.000.000	84.000.000
	Total	84.000.000	84.000.000

PART V: OPERATIONAL ORIENTATION AND TARGETS FOR 2025

I. Plan and orientation of the Board of Directors

Although 2024 is still a difficult year for the Vietnamese veterinary industry, due to the livestock sector still being affected and significantly impacted by African swine fever, leading to a sharp decline in the total pig herd nationwide. In addition, the impact of the Covid pandemic has generally affected the economy of the whole world, leading to the suspension of goods circulation and high raw material prices;

However, to align with the current business situation of the company, the Board of Directors has agreed on some targets in the business production plan for 2025 as follows:Net revenue: 124,200,000,000 VNDProfit after tax: 5,100,000,000 VND

In 2025, the Board of Directors will continue to hold meetings and organize Board of Directors sessions to implement the resolutions of the annual General Meeting of Shareholders in 2025, while carrying out the company's management work to enhance business efficiency.

+ In 2025, the Board of Directors will continue to supervise the daily operating apparatus while assigning the Director of the company to update and prepare financial reports to send to the Board of Directors to develop strategic plans for the following month.

II. Main objectives of the company

The difficult conditions of the company, the Board of Directors will focus on implementing some specific tasks as follows:

1. General objective

- Focus on directing the implementation of the flexible and responsive business production plan for 2025, striving to minimize risks, seize opportunities while maintaining stable and effective business operations to create conditions for increasing income for the company's employees.

Ecoming a Brand and Reputable Enterprise in the Field of Investment in Veterinary Medicine, Aquaculture Medicine, and Various Vaccines.

Stabilizing, developing sustainably, and gradually expanding the operational market to provinces and cities across the country where the company has strengths, improving, diversifying products in line with the general situation, and continuously enhancing product quality.

+ **Objectives for Business Production Activities:** : Developing stably and sustainably. The company carries out the production and trading of veterinary medicines while providing a variety of veterinary products such as: injectable antibiotic solutions, sterile injectable antibiotic powders, oral antibiotic solutions, liquid medicines, parasiticide medicines, oral powders, vitamins and enhancers, disinfectants.

Aquaculture Medicines: The company currently provides medicinal products for aquaculture including antibiotics, nutritional medicines, parasiticide medicines, and disinfectants. The company produces and trades high-quality products, diverse and rich in types for animals, pets, livestock, and poultry, from medicines for disease prevention and treatment, parasiticide medicines, health supplements, growth stimulants to reproductive regulation medicines, parasiticide medicines, and antifungal medicines.

To ensure the development of business activities, the company conducts annual reviews to consolidate old customers and build a new customer system, through annual sales will reassess the standards of level 1 and 2 agents in provinces and cities nationwide; Implementing sales marketing through various channels: online (website), wholesale and retail agents at the company store; Promoting the maintenance of good customer care by establishing a technical team to perform surgeries, pathological examinations, and technical consultations for farms and breeders; Conducting regular training activities on professional expertise in using veterinary medicines... for market staff and sales staff;

Financial Objectives: Building a healthy, self-sufficient financial foundation.

Human Resource Objectives: Improving the quality of the workforce in terms of quantity, ensuring quality.

2. Medium and Long-Term Development Strategy

In the coming time, the company, in addition to focusing on producing high-quality products to best serve market needs, will also focus on promoting product consumption through market expansion and diversifying customer groups. Along with that, the company will also aim to enhance commercial activities such as trading vaccines to prevent diseases for livestock and poultry, thereby strengthening the connection between farmers and the company.

Strategy for Business Production Activities: Expanding the scope of operations, gradually creating a solid foundation.

Strategy for Slogan and Business Strategy: Taking service as the business objective, taking business results as the driving force for development.

Strategy for Quality Policy: Continuously innovating and improving product quality is the mission of the enterprise.

Financial Strategy: Promoting the effective use of self-owned capital, gradually increasing capital to meet the production and business needs of each period, while expanding relationships with...partners, investors, banks, credit institutions to exploit external capital.

Corporate Culture Building Strategy: Propagate for employees to strictly comply with the state laws and the company's internal regulations. Ensure good rights for employees. Create conditions for organizations within the company to operate.

III. Implementation Directions:

In the year 2025, the Company strives to effectively implement specific development directions and business strategies for the year 2025 as follows:

1. Product Development Work

Work Consolidate, maintain, develop, enhance productivity, and improve the products of the veterinary medicine manufacturing plant to meet market demands in terms of quality and market preferences. Continue to inspect, review, complete, and develop the product catalog of the Company according to the direction of creating effective product lines suitable for the changing disease situation in Vietnam. Enhance product value so that the sales system can develop sales on the market and provide motivation for sales personnel in the system.

2. Marketing Work

Implement product promotion on the Company's website. Build advertising programs on media for strategic products, develop sales channels, and promote products on the Company's website. Enhance product value so that the sales system can develop sales on the market and provide motivation for sales personnel in the system. Coordinate with the testing department to issue product testing procedures for more accurate work. Complete

and build the system of processes and work standards for marketing work towards professionalism, consistency, and support for the entire sales system in building traditional and modern marketing programs suitable for sales programs, market segmentation, and target customers. Develop advertising, communication, and attract potential customers through direct and indirect channels to convey product information to interested parties in the most convenient, friendly, and approachable manner. Build advertising programs on media for strategic products.

3. Sales System Building Work and Business Strategy

Complete and develop the sales system in all three regions: Northern, Central, and Southern Vietnam through specific measures: Train sales skills, communication, product knowledge; build sales policies suitable for each market area; establish regimes. Sales Quotas, Income, Compensation Policies for Sales Personnel Suitable to Create Motivation in Sales Work.

Searching for export markets to effectively exploit the capacity of factories as well as stabilize and increase market share.

Growth Strategy in Depth: Finding opportunities to enhance the efficiency of the enterprise by expanding products and markets, penetrating new markets, increasing the market share of existing products in current markets. Regarding production, we will develop existing production lines, focus on strengths, expand production, improve and perfect our production lines to become modern, thereby creating profitability.

4. Planning and Production Implementation Work

Maximizing cost savings to bring the lowest product cost. The company has continuously improved planning and production implementation through specific measures:

Perfecting the production staff team to serve business production work;

Building work processes suitable to reality and ensuring work efficiency;

Developing specific plans for raw materials, production plans for the year, monthly, quarterly in 2025 to increase proactivity in production service stages.

5. Financial Work and Financial Structure

5.1. Financial Work

Organizing the accounting system activities according to the prescribed standards, fully and accurately reflecting the data. Organizing the implementation of regulations and processes for document circulation to account quarterly according to the fiscal year so that the Board of Directors can make decisions and adjust business plans as quickly and effectively as possible, while also meeting the annual reporting requirements according to the Enterprise Law and Securities Law.

Tightly managing assets, cash flow, and inventory assets. Finding suitable solutions to promote business production, creating the fastest cash flow cycle; maximizing cost savings effectively and appropriately; organizing well the import, purchasing, transportation, and storage of goods with consideration

suitable for actual business needs to minimize inventory levels. Timely detection and immediate handling to avoid capital stagnation.

Organizing the management of the production and business process smoothly, rhythmically, minimizing the idle time of machinery and equipment. Effectively implementing after-sales services with customers to strengthen long-term relationships with the company. Implementing flexible policies for each specific customer, especially potential customers, to create a good initial impression.

Enhancing the efficiency of fixed capital and working capital utilization. Building a capital mobilization strategy suitable for the market situation and business environment of each period.

5.2. Financial Structure

The management of cash and cash equivalents needs to be calculated and reasonably reserved for the cash fund. Therefore, the Board of Directors and the Executive Board need to build a reasonable capital structure to match the characteristics of production and business activities and achieve the goal of minimizing capital usage costs.

Completing the Management Work, Arranging and Organizing a Lean Apparatus, Enhancing the Executive Capacity of Management Officials through Standardizing Responsibilities and Tasks.

Building a training plan and enhancing the professional qualifications and management skills for the team of officials and employees who are responsible for their work, sensitive to market conditions, dynamic in business, and timely supplementing the source of officials with sufficient capacity to meet the requirements of innovation in the business methods of the enterprise.

6. Organizational Structure

Always maintain, train a strong workforce, ensure professionalism, dynamism, and creativity in work, good management, and be proactive in all situations. Investing in human resources, officials, and employees of the Company in every department is always a decisive factor determining the results of work.

Recruiting talented individuals can be done through various forms such as training staff in each department in a concentrated manner, recruiting employees with deep

professional qualifications, or operating in the form of collaborators. There are incentive policies to attract and retain capable labor.

Continuing to perfect the system of internal management documents that are appropriate and effective for all activities of the Company. Implementing the system of specific standards to evaluate labor quality.

The Board of Directors believes that having additional strategic investors and professional securities investors accompanying the Company will further enhance business management capacity as well as provide many new solutions to support the Company. At the same time, it will resolve the difficulties of the Company and gradually bring the Company back to effective business operations in the near future.

Above is the activity report of the Board of Directors of Central Pharmaceutical Joint Stock Company I in the year 2024 and the plan for 2025, respectfully submitted to the General Meeting of Shareholders for approval.

Thank you very much!

**ON BEHALF OF THE BOARD OF
DIRECTORS**
chairman of the board of directors



NGUYEN ANH TUAN

Hanoi, April 1, 2025

REPORT OF THE AUDIT COMMITTEE
VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

(Presented to the Annual General Meeting of Shareholders 2025)

Dear Shareholders and Distinguished Delegates.

- Based on the Charter and operational regulations of the Vietnam Veterinary Products Joint Stock Company I
- Implementing the functions and tasks assigned, the Audit Committee of the Joint Stock Company of Central Veterinary Medicine I has conducted control over the Company's operations in 2024, now wishes to report to the General Meeting of Shareholders with the main contents as follows:

Part I: Summary of the activities of the Audit Committee.

- The Audit Committee has operated according to the Enterprise Law and the Company's Charter, on behalf of the Shareholders to control the production and business activities and management of the Company.

The Audit Committee has assigned specific tasks to each member in each field suitable to their professional qualifications. The members regularly exchange information, work via email, phone, and direct communication, ensuring smooth and timely communication, in line with the Company's operational and production activities

In 2024, the Audit Committee organized 02 meetings regarding the activities of the Audit Committee in the first 6 months of the year and summarized the activities of 2024. The meetings were fully attended by the participating members

The members of the Audit Committee have made efforts to fully participate in all Board of Directors meetings and have also accessed all production and business activities of the Company.



Part II: Remuneration and other benefits of the Audit Committee

The remuneration of the Board of Directors and the Audit Committee in 2024 has been disbursed according to Resolution No. 19-2024/NQ AGMS of the Company's General Meeting of Shareholders approved on 04/05/2024 and is detailed in the financial report for 2024, specifically:

Unit of measurement: dong

No.	DESCRIPTION	AMOUNT OF COMPENSATION RECEIVED ACCORDING TO NQ No. 19 2024 /NQ AGM
1	Nguyen Anh Tuan	36.000.000
2	Nguyen Viet Hoang	24.000.000
3	Phan Quoc Duy	16.000.000
4	Bui Huong Lien	8.000.000
	Total	84.000.000

Part III: Results of monitoring the operational and financial situation of the Company

1. Results of production and business activities in 2024 of the Company:

At the end of the 2024 financial year, the Board of Directors directed the Executive Board to prepare the financial report, and the financial report was audited by UHY Audit and Consulting Company Limited.

The Supervisory Board agreed with the assessments of the operations and finances in the Company's financial report and the auditing unit with the main indicators as follows:

Results of production and business activities in 2024

Unit: Thousand dong

Financial indicators	Year 2023	Year 2024	% increase/decrease
Net revenue from sales of goods and rendering of services	94.339.484.657	109.113.684.605	15,66%
Operating profit	2.588.981.277	4.274.591.547	65,11%
Net profit before tax	4.268.778.453	5.093.646.511	19,32%

Financial indicators	Year 2023	Year 2024	% increase/decrease
Net profit after tax	3.381.284.688	3.777.670.212	11,72%
Current liabilities	41.548.941.702	42.042.724.462	1,19%
Profit distribution	0%	0%	

(Source: Consolidated audited financial statements for 2024 of Central Vietnam Veterinary Products Joint Stock Company I)

- According to the financial report for 2024 ending on 31/12/2024, the results achieved are as follows:

+ Net revenue from sales and services reached: 109,113,684,605 dong, only achieving 99.19% of the annual plan.

+ Profit after tax reached: 3,777,670,212 dong, only achieving 75.55% of the annual plan.

+ Short-term liabilities decreased by 41,548,941,702 dong, an increase of 1.19% compared to the same period last year.

UBKT evaluates the financial statements for 2024 to be prepared and presented honestly, in accordance with Vietnamese accounting standards and current regulations.

In 2024, no fraud or potential fraud risks were detected in the financial statements.

2. Transactions with Subsidiaries and Related Parties of the Company

Transactions between Central Veterinary Medicine Joint Stock Company I and its subsidiaries and related parties are conducted in accordance with regulations. The Audit Committee did not detect any abnormalities in these transactions.

Part IV: Results of Monitoring the Board of Directors and Executive Board

- In 2024, the Board of Directors of the Company held direct meetings. All meetings were conducted in accordance with the procedures specified in the Charter of Central Veterinary Medicine Joint Stock Company I and the Enterprise Law. Through the actual situation and the audited financial statements of the Company, the Audit Committee also did not find anything unusual in the operation and management process of the Company.

- The Executive Board has made significant efforts in managing the Company's production and business activities according to the direction set by the Board of Directors. However, the accumulated losses over many consecutive years remain a significant financial pressure for the Company. The Board of Directors and the Executive Board have also actively

sought solutions to enhance and consolidate the market, regain the Company's market share by implementing an increase in the number of new products, new product lines, as well as improving product quality to bring to the market, and closely connecting with the entire customer system.

- The Board of Directors sets the plan target for 2025 with net revenue of 124,200,000,000 VND and after-tax profit of 5,100,000,000 VND, which is appropriate for the actual situation.

Part V: Results of Evaluating the Internal Control System and Risk Management of the Company, Assessing the Independence and Objectivity of the Independent Audit

The implementation of internal control is well executed, ensuring that business units follow the correct procedures. The Company has issued and strictly implemented internal control and risk management processes in accordance with legal regulations. The selected auditing company (UHY Auditing and Consulting Company Limited) ensures reliability, honesty, compliance with audit deadlines, adherence to professional regulations, and maintains independence and objectivity when providing audit opinions. The Audit Committee did not detect any issues regarding conflicts of interest, independence, or objectivity of the auditors, the audit team, or the auditing company when conducting audit work.

Part VI: Plan Targets for 2025 and Implementation Solutions of the Audit Committee

I. Current Situation at the Company

Through the process of reviewing the activities of the entire Company, the Board of Directors and the Audit Committee have agreed to require the branch to complete the tax inspection for all years that have not been inspected to date and prepare all procedures to close the tax code due to the branch's ineffective operation and lack of feasible direction to resolve existing issues.

At the Ho Chi Minh City branch, the tax debt situation has just been resolved, therefore the tax code closure at the Ho Chi Minh City branch has not yet been implemented

II. Plan targets for 2025:

The year 2025 is a year significantly affected by fluctuations in the economy. Based on the revenue and profit results achieved in 2024, the Board of Directors has established the plan targets for 2024 with a net revenue of 124,200,000,000 VND and a post-tax profit of 5,100,000,000 VND, which is appropriate for the actual situation. However, the Board of Directors needs to clearly recognize the existing difficulties of the Company to have appropriate policies and timely directives for the Executive Board to organize implementation to achieve the goals.

III. Recommendations and Solutions for implementation in 2025 for the Board of Directors

1. Recommendations:

Based on the actual business situation of 2024, our Audit Committee makes the following recommendations:

The Company needs to continue reviewing and evaluating personnel work, continue restructuring to enhance the operational efficiency of the units.

The Company needs to have a clear direction in its business strategy, consolidate and stabilize what the company already has, serving as a basis and premise for new development, improving and enhancing capacity based on development trends in the specific industry.

2. Solutions:

In 2025, the Company's financial situation has somewhat resolved the difficulties. For the Company to develop, the Audit Committee recommends implementing the following basic solutions:

a. For the office at 88 Truong Chinh:

The revenue obtained in the year mainly comes from leasing premises, in addition, the number of staff operating the entire workload of the unit at the office is only 3 people. Therefore, the Board of Directors and the Executive Board need to have a plan to strengthen the workforce. The Company also needs to have a compensation policy that is commensurate with the general standards of each position and each common task across the entire Company system, ensuring alignment with the contributions of each employee so that workers can fully utilize their capabilities to bring benefits to the Company as well as to the employees.

Implement the development of veterinary medicine business at the Company office to create a source to offset payable costs.

b. For Central Veterinary Company Limited 1

** With the overall activities of the entire company:*

Although the economy faces many difficulties, the Board of Directors and the Executive Board have united to propose directions for the production and business activities of the entire company, but the results achieved are still limited. The Board of Directors and the Executive Board have been and are making great efforts to implement Resolution No. 19/2024/NQĐHĐCĐ of the General Meeting of Shareholders. Therefore, in 2025, the

company needs to strive to improve product quality and increase more products in the market to gain market share.

regaining market share, increasing sales, and promoting the effectiveness of investment capital. Urgently rectify and complete the accumulated losses to bring benefits to the shareholders of the company.

*** With the production and business activities of Veterinary Medicine and Aquaculture:**

The diseases related to livestock are always complicated, therefore the Company needs to focus resources on researching new products suitable for each period and organizing production to timely supply the market. The Company needs to have appropriate sales care policies so that customers can cooperate and accompany the Company in business activities, ensuring that both parties are assured of their entitled benefits.

In addition, it is necessary to select members who have enough dedication, capability, and enthusiasm in business activities, while the company also needs to have a compensation policy that is commensurate with the contributions of each employee so that workers can wholeheartedly promote their abilities, bringing benefits to both the company and the employees.

Dear Congress, the Audit Committee recognizes that to date, the difficulties of the Company have been somewhat alleviated. If there is effort from the Board of Directors, the Executive Board, the Audit Committee believes that in 2025, the Company will overcome some difficulties, achieve the set goals, and meet the expectations of the shareholders.


Above is the activity report of the Audit Committee of Central Veterinary Medicine Joint Stock Company I in the past period, respectfully submitted to the General Meeting of Shareholders for approval.

The Audit Committee sincerely thanks the esteemed Shareholders

Wishing the congress success./.

ON BEHALF OF THE AUDIT COMMITTEE

Chairman of the Audit Committee



NGUYEN VIET HOANG.

Hanoi, April 1, 2025

NOMINATION AND CANDIDATE REGULATIONS

ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS

TERM 2022-2027

Pursuant to:

- *Enterprise Law No. 59/2020/QH14 was passed by the 14th National Assembly of the Socialist Republic of Vietnam at the 9th session on June 17, 2020, effective from January 1, 2021.*
- *Contract Law No. 54/2019/QH14 dated November 26, 2019 and documents guiding its implementation.*
- *The Charter of Central Veterinary Products Joint Stock Company I was amended at the 2023 Annual General Meeting of Shareholders approved on May 6, 2023;*
- *Pursuant to the Internal Regulations on the Governance of Central Veterinary Products Joint Stock Company I, which were amended at the 2022 Annual General Meeting of Shareholders approved on May 28, 2022*
- *Pursuant to the Resolution of the Annual General Meeting of Shareholders dated April 26, 2025 approving the election of additional members of the Board of Directors for the 2022-2027 term*

Chapter I: GENERAL PROVISIONS

Article 1. Purpose, scope of regulation and subjects of application. 1. This regulation is established to specify the principles and methods of nomination, candidacy and election of additional members of the Board of Directors (BOD) for the 2022-2027 term of Central

M.S.D.A.

Veterinary products Joint Stock Company I at the 2025 Annual General Meeting of Shareholders approved on April 26, 2025.

2. The Regulations are applicable to all Shareholders owning shares of Central Veterinary products Joint Stock Company I (according to the VSDC list as of March 26, 2025)

Article 2. Rights and obligations of Shareholders and authorized representatives attending the 2025 Annual General Meeting of Shareholders.

1. Each Shareholder or authorized representative attending the General Meeting shall receive a ballot for the election of additional members of the Board of Directors, on which the number of shares held by the Shareholder or authorized representative of that Shareholder and the corresponding number of votes used for the election shall be clearly stated.

2. Shareholders must comply with the conditions and procedures specified in this Regulation, the guidance of the Election Committee and the Chairman of the General Meeting.

CHAPTER II: REGULATIONS ON NOMINATIONS AND CANDIDATES FOR

ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS FOR THE TERM 2022-2027

Article 3. Number, term, and standards of members of the Board of Directors.

1. The number of additional members of the Board of Directors elected is 01 non-executive member of the Board of Directors.

2. The term of office of the additional elected Board of Directors member is from 2025-2027; Board of Directors members can be re-elected for an unlimited number of terms

3. Standards and conditions for non-executive Board of Directors (BOD) members.

Board of Directors members must satisfy the standards for being a member of the Board of Directors as prescribed in the Enterprise Law, the Company Charter, the Internal Governance Regulations and this Regulation, specifically:

a) Have full civil act capacity, not being a subject not allowed to manage an enterprise as prescribed in Clause 2, Article 17 of the Enterprise Law.

b) Have professional qualifications and experience in business administration or in the Company's business fields, industries and professions and not necessarily being a Shareholder of the Company.

c) Be in good health, have good moral qualities, be honest, upright, and have a sense of law compliance.

d) Can be a member of the Board of Directors of another Company at the same time, but cannot be a member of the Board of Directors of more than 05 other Companies at the same time.

Article 4. Right to nominate and run for additional members of the Board of Directors.

- Shareholders holding common shares have the right to aggregate their voting rights to nominate and run for election to the Board of Directors.
- The number of candidates that each group has the right to nominate depends on the number of candidates decided by the General Meeting and the share ownership ratio of each group. Shareholders or groups of Shareholders holding (as of the closing date of the list of Shareholders, March 26, 2025).
- . Shareholders or groups of shareholders holding from 10% of the total number of common shares have the right to nominate candidates for the Board of Directors, specifically:
 - Shareholders and groups of Shareholders holding from 10% to less than 20% of the number of common shares have the right to nominate and run for a maximum of 01 candidate.
 - Shareholders or groups of shareholders holding from 20% to less than 30% of common shares have the right to nominate and run for a maximum of 02 candidates.
 - Shareholders or groups of shareholders holding from 30% to less than 50% of common shares have the right to nominate and run for a maximum of 03 candidates.
 - Shareholders or groups of shareholders holding more than 50% of common shares have the right to nominate and run for a maximum of candidates according to regulations.
- In case the number of additional candidates for the Board of Directors through nomination and candidacy is still not enough (the number of candidates must be equal to or greater than the number of members. According to the provisions of Clause 5, Article 115 of the Law on Enterprises, the Board of Directors is approved by the General Meeting of Shareholders for election at the meeting), within 03 (three) days before the time of the General Meeting of Shareholders, the incumbent Board of Directors may nominate additional candidates, the

candidates introduced by the Board of Directors must be approved by a majority of the members of the Board of Directors. The list of candidates for the Board of Directors will be approved by the General Meeting of Shareholders before the election.

Article 5. Nomination and candidacy documents for election to supplement the Board of Directors

- Nomination and candidacy documents for election to the Board of Directors, including:
 - + Application form or nomination form for candidates to join the Board of Directors,
 - + CV self-declared by the candidate with photo attached
 - + Valid copy of ID card/CCCD/Passport;
 - + Valid copy of permanent residence registration (or long-term temporary residence registration);
 - + Valid copies of degrees, diplomas and certificates certifying educational level and professional qualifications;
 - + Authorization letter and/or group meeting minutes (if the candidate is authorized by the group to run for election).
- Nomination and candidacy documents must be sent to Central Veterinary Products Joint Stock Company I no later than 4:00 p.m., April 15, 2025, at the address: 88 Truong Chinh, Phuong Mai Ward, Dong Da District, Hanoi. Phone: 0243.8691262, 0988286335, Fax: 0243.691263;
- In case the submitted documents are faxed or scanned, the original must be sent back when registering to attend the meeting before the meeting begins.
- Only nomination and candidacy documents that meet the nomination and candidacy requirements and candidates who meet the corresponding requirements of the Board of Directors will be included in the list of candidates announced at the General Meeting of Shareholders.

Chapter III: ELECTION OF ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS, TERM 2022-2027

Article 6. Selection of candidates.

- Based on the nominations and candidacy of Shareholders, groups of Shareholders and the attached documents of the candidates, the Board of Directors will make a list of candidates who meet the prescribed conditions to elect additional members of the Board of Directors for the 2022-2027 term.

Article 7. Election principles.

- The election of additional members of the Board of Directors shall be conducted according to the following principles:
- Comply with current laws on enterprises in Vietnam.
- Ensure publicity, democracy and legal rights of all Shareholders
- The structure of the number of additional members of the Board of Directors is: 01 Member

Article 8: Voters

- Voters at the General Meeting of Shareholders are shareholders who own shares or persons authorized by shareholders to attend the meeting (according to the list of shareholders as of March 26, 2025) present at the General Meeting of Shareholders.

Article 9. Form and method of election.

- The election of additional members of the Board of Directors will be conducted in the form of direct, secret ballot at the meeting according to the cumulative voting method (stipulated in Clause 3, Article 148, Enterprise Law No. 59/2020/QH14).
- After the General Meeting of Shareholders approves the list of candidates for additional members of the Board of Directors and approves the election procedures, each shareholder attending the meeting will be given 01 ballot by the Organizing Committee: one ballot to elect additional members of the Board of Directors. Shareholders are responsible for checking the information on the ballot, if there are any errors, they must immediately report to the Organizing Committee.
- The ballot clearly states the list of candidates arranged in order A, B, C; Shareholder code, number of shares owned/represented, number of voting shares, with the Company's seal. - Each Shareholder has a total number of votes corresponding to the total number of shares

owned (including shares owned by himself and shares authorized to be owned) multiplied by the number of additional members elected to the Board of Directors, specifically according to the following formula:

Election of members of the Board of Directors.

Total number of votes = Total number of shares with voting rights X Number of elected members of the Board of Directors

- Shareholders have the right to concentrate all their total voting rights on one or several candidates, provided that the total number of votes for that candidate(s) is not higher than the total number of votes they have.

Article 10. Ballot Counting Committee.

- The Ballot Counting Committee is nominated by the Presidium and approved by the General Meeting of Shareholders.
- Members of the Ballot Counting Committee must not be on the list of nominees and candidates for the Board of Directors
- The Ballot Counting Committee must ensure honesty, objectivity, and confidentiality of information regarding the vote counting and election.
- The Ballot Counting Committee has the following tasks:
 - + Check and announce the list of candidates for the election of additional members of the Board of Directors,
 - + Submit to the General Meeting of Shareholders for approval of the Election Regulations and Election Rules.
 - + Provide instructions on how to vote and organize the election for Shareholders.
 - + Distribute and collect ballots.
 - + Conduct vote counting, prepare minutes of vote counting, announce vote counting results to the General Meeting of Shareholders.
 - + Together with the Chairman of the General Meeting, review and resolve complaints and denunciations about candidates as well as election results (if any) and report to the General Meeting of Shareholders for decision.

+ The Election and Ballot Counting Committee is fully responsible before the law and the General Meeting of Shareholders for compliance with these regulations and for the accuracy of vote counting results.

Article 11. Voting and counting of votes.

- Voting begins when the ballots are distributed and ends when the last shareholder puts his/her ballot into the ballot box.

- The Ballot Counting Committee shall check the ballot box in the presence of the Shareholders.

The Ballot Counting Committee shall conduct the counting of votes at the polling station and immediately after the voting is completed.

- After the counting of votes, the Ballot Counting Committee shall prepare a record of the vote counting results and the Head of the Ballot Counting Committee shall announce it to the General Meeting.

Article 12. Principles for determining election results.

- The candidates elected as additional members of the Board of Directors are determined by the number of votes from high to low, starting from the candidate with the highest number of votes until the number of members of the Board of Directors is sufficient.

- In case there are 2 or more candidates with the same number of votes, the candidate holding more shares will be selected. If the number of shares held is equal, a re-election will be conducted among the candidates with the same number of votes.

Article 13. Preparation and publication of the vote counting minutes.

- After counting the votes, the Ballot Counting Committee must prepare the vote counting minutes.

- The vote counting minutes must have the following main contents:

- Time and place of preparation of the vote counting minutes.

- Total number of ballots issued and collected, number of ballots not returned by Shareholders.

- Election results.

- Signature of the member of the Ballot Counting Committee.
- The vote counting minutes must be announced by the Ballot Counting Committee before the General Meeting.

Article 14. Right to question.

- Shareholders/authorized representatives of Shareholders have the right to question and complain about the election and vote counting. The Chairman of the meeting and the Vote Counting Committee are responsible for explaining and clarifying the questions of Shareholders/authorized representatives of Shareholders and recording them in the minutes of the General Meeting of Shareholders.

Article 15. Effectiveness of the Regulations.

This Regulation takes effect immediately after being approved by the General Meeting of Shareholders and only applies to the candidacy, nomination and election of additional members of the Board of Directors for the 2022-2027 term at the 2025 Annual General Meeting of Shareholders of Central Veterinary Products Joint Stock Company I.

Recipients:

- General Meeting of Shareholders;
- Board of Directors, Audit Committee;
- Board of Directors' records.

TM. GENERAL MEETING OF
SHAREHOLDERS

CHAIRMAN



NGUYEN ANH TUAN

Appendix

INSTRUCTIONS FOR ELECTING ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS, TERM 2022-2027

(Cumulative voting method)

Type of ballot, There is 01 type of ballot including:

- Ballot for the Board of Directors (BOD)

Voting method: Shareholders/Authorized representatives of Shareholders shall cast ballots to elect additional members of the Board of Directors in the ballot box.

Voting method: Each Shareholder has a total number of votes corresponding to the total number of shares with voting rights (including owned and authorized votes) multiplied by the number of elected members of the Board of Directors.

Shareholders can divide their total number of votes among the candidates they choose or concentrate all their total votes on one or several candidates, but must ensure that the total number of votes for the candidates does not exceed the total number of votes of that Shareholder; and the number of candidates that the Shareholder chooses to vote for must not exceed the number of candidates needed to be elected to the Board of Directors (approved by the General Meeting).

For example:

- Suppose the General Meeting votes to elect 01 additional member of the Board of Directors, term 2022-2027 from a total of 02 candidates.

Shareholder Nguyen Van A holds (including owned and authorized shares) 1,000 voting shares. Then the total number of votes of Shareholder Nguyen Van A is $1,000 \times 1 = 1,000$ votes.

Shareholder Nguyen Van A can select a maximum of 01 candidate out of 02 candidates to elect to the Board of Directors and the total number of votes for the candidates that Shareholder Nguyen Van A selects must not exceed 1,000 votes.

Shareholder Nguyen Van A can vote cumulatively in the following way:

Shareholder Nguyen Van A casts all his votes for 1 candidate (equivalent to the selected candidate receiving all 1,000 votes).

NO.	FULL NAME OF CANDIDATE	CUMULATIVE VOTE	NUMBER OF VOTES
1	Candidate 1		0
2	Candidate 2	<input checked="" type="checkbox"/>	1.000

Invalid ballots.

Cases of invalid ballots are specified in Clause 4, Article 13 of this Regulation, specifically in one of the following cases:

- Ballots not issued by Central Veterinary Products Joint Stock Company I and/or do not have the Company's seal.
- Ballots with crossed out, corrected, or supplemented contents that are not in accordance with regulations (in case of incorrect writing, a new ballot must be exchanged).
- The ballot contains additional or incorrect names, or is not on the list of candidates approved by the General Meeting of Shareholders before the vote.
- The ballot has a total number of voting rights for candidates exceeding the total number of voting rights of that Shareholder (including ownership and authorization rights).
- The ballot is not signed and clearly states the full name of the Shareholder/authorized representative of the Shareholder.
- The ballot votes for more candidates than the number required to be elected.
- The ballot does not state the number of votes for any candidate.

Hanoi, April 1, 2025

SUBMISSION

**Re: Approval of Mr. Phan Quoc Duy's resignation from the Board of Directors and
proposal to add members to the Board of Directors**

**TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to the Law on Enterprises 2020 and implementing documents;
- Pursuant to the Charter of Central Veterinary products Joint Stock Company I;

**The Board of Directors respectfully submits to the General Meeting of Shareholders
for consideration and approval the following contents:**

- Approval of Mr. Phan Quoc Duy's resignation from the Board of Directors for the 2022-2027 term
- Approval of the election of additional members of the Board of Directors and Approval of the list of nominees for additional members of the Board of Directors.

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS
chairman of the board of directors**



NGUYỄN ANH TUẤN

Hanoi, April 1, 2025

SUBMISSION

Re: Through the Report of the Board of Directors

**TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

**The Board of Directors respectfully submits to the General Meeting of Shareholders for
consideration and approval the following contents:**

Report on the Company's Board of Directors' activities in 2024 and orientation for 2025;

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS
chairman of the board of directors**



NGUYỄN ANH TUẤN

Hanoi, April 1, 2025

SUBMISSION

Re: Approval of the Audit Committee's Report

TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary products Joint Stock Company I

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following contents:

Audit Committee's performance report in 2024 and Audit Committee's task implementation plan in 2025

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS
chairman of the board of directors**



NGUYỄN ANH TUẤN

**VIETNAM VETERINARY
PRODUCTS JOINT STOCK
COMPANY I**

(VINA VETCO)

No: 12 -2025 /TTr-DHĐCĐ

**SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness**

Hanoi, April 1, 2025

SUBMISSION

Re: Approval of the Audited Financial Report for 2024

**TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.


**The Board of Directors respectfully submits to the General Meeting of Shareholders for
consideration and approval the following contents:**

Approving the 2024 audited financial statements of Central Veterinary Medicine Joint Stock Company I, independently audited by UHY Auditing and Consulting LLC, signed on March 28, 2025.

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS
chairman of the board of directors**



NGUYỄN ANH TUẤN

Hanoi, April 1, 2025

SUBMISSION

Re: Profit distribution plan for 2025

TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary products Joint Stock Company I

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following contents:

1. Profit distribution in 2024: No dividend payment.
2. The 2025 profit distribution will be decided by the 2026 Annual General Meeting of Shareholders based on the Company's 2025 production and business results after fulfilling its obligations to the State budget and other financial obligations as prescribed by law.

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS**

chairman of the board of directors



NGUYỄN ANH TUẤN

**VIETNAM VETERINARY
PRODUCTS JOINT STOCK
COMPANY I**

(VINAVETCO)

No: 14 -2025 /TTr-DHĐCĐ

**SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness**

Hanoi, April 1, 2025

SUBMISSION

***Re: Approval of remuneration of the Board of Directors, Audit Committee, and
Corporate Governance***

**TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.

**The Board of Directors respectfully submits to the General Meeting of Shareholders for
consideration and approval the following contents:**

1. The final settlement of remuneration of the Board of Directors and the Audit Committee in 2024 according to Resolution No. 19-2024/NQ-ĐHĐCĐ dated May 4, 2024 of the General Meeting of Shareholders is as follows:

- Remuneration paid to the Board of Directors is: VND 84,000,000

2. Proposed remuneration for members of the Board of Directors and Audit Committee in 2025 as follows:

- Chairman of the Board of Directors: VND 3,000,000/month

- Member of the Board of Directors: VND 2,000,000/month

- Company Administrator: VND 2,000,000/month

Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**ON BEHALF OF THE BOARD OF
DIRECTORS
chairman of the board of directors**



NGUYỄN ANH TUẤN

**VIETNAM VETERINARY
PRODUCTS JOINT STOCK
COMPANY I**

(VINA VETCO)

No: 15 -2025 /TTr-DHĐCĐ

**SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness**

Hanoi, April 1, 2025

(Re: Approval of the Selection of an Audit firm for the 2025 Financial Statements)

**TO : The 2025 Annual General Meeting of Shareholders of Central Veterinary
products Joint Stock Company I**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;*
- Pursuant to the Charter of organization and operation of Central Veterinary products Joint Stock Company I.*

**The Audit Committee respectfully submits to the Company's General Meeting of
Shareholders for consideration and approval of the following content:**

To ensure proactive selection of a suitable auditing unit, meeting the Company's requirements on implementation time and service quality, the Audit Committee respectfully requests the General Meeting of Shareholders to authorize the Audit Committee to select an auditing company listed in the list of independent auditing companies qualified to audit according to current regulations to conduct the audit of the semi-annual financial statements for 2025 and the financial statements for 2025 (Quarterly financial statements can be reviewed if necessary at the request of the State management agency). Respectfully submit to the Company's General Meeting of Shareholders for consideration and approval.

Yours sincerely!

**INDEPENDENT MEMBER OF THE BOARD OF DIRECTORS
Chairman of the Audit Committee**



NGUYỄN VIỆT HOÀNG